Results 211 to 220 of about 22,196 (255)
Some of the next articles are maybe not open access.
Endocrine Practice, 2012
OBJECTIVE To investigate the effect of Bromocriptine-QR on glycemic control in patients with type 2 diabetes whose glycemia is poorly controlled on one or two oral anti-diabetes agents.
A. Vinik +5 more
semanticscholar +1 more source
OBJECTIVE To investigate the effect of Bromocriptine-QR on glycemic control in patients with type 2 diabetes whose glycemia is poorly controlled on one or two oral anti-diabetes agents.
A. Vinik +5 more
semanticscholar +1 more source
Bromocriptine and Endocrine Disorders
Annals of Internal Medicine, 1979Excerpt To the editor: Drs. Spark and Dickstein have presented an excellent overview of the role of bromocriptine in the treatment of endocrine disorders (1).
G. M. Besser +3 more
openaire +3 more sources
Bromocriptine treatment of acromegaly
Metabolism, 1977Bromocriptine at a dose of 7.5-30 mg/day was given to 12 acromegalics for 6 mo. Mean serum growth hormone (GH) levels during a glucose tolerance test (GTT) were significantly lowered by the drug. In four patients the serum GH response during a GTT was suppressed to normal (i.e. less than or equal to 5 mlU/liter).
Keith Mashiter +2 more
openaire +2 more sources
Bromocriptin-induzierte Pleuropneumopathie
DMW - Deutsche Medizinische Wochenschrift, 2008A 64-year-old man was diagnosed to have Parkinson's disease when aged 42 years and since then has been treated with levodopa and benserazide (up to 875 mg daily). Bromocriptine (up to 35 mg daily) was added to the medication 9 years ago. 3 1/2 years ago he developed exertional dyspnoea (NYHA class II-III) and lost 5 kg in weight.
P. Greminger +4 more
openaire +3 more sources
Surveillance of Bromocriptine in Pregnancy
JAMA: The Journal of the American Medical Association, 1982Information was collected on the outcome of 1,410 pregnancies in 1,335 women to whom bromocriptine mesylate (Parlodel) had been given, primarily in the early weeks of pregnancy. These Pregnancies resulted in 197 early terminations (14%) (including 25 induced abortions [1.8%) and in 1,213 births (86%). The incidence rate of spontaneous abortions (11.1%),
Pierre Krupp, Peter Braun, Ivan Turkalj
openaire +4 more sources
Huntington's Chorea and Bromocriptine
Archives of Neurology, 1979To the Editor.— We read with interest the letter from Frattola et al (35:60, 1978) about the mechanisms of action of bromocriptine in Huntington's chorea. According to the authors, bromocriptine should be considered as a partial dopaminergic agonist, with a "biphasic effect" that depends on the dosage.
ALBANO, CLAUDIO, COCITO, LEONARDO
openaire +4 more sources
Bromocriptine and Pleuropulmonary Disease
Archives of Internal Medicine, 1989Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically since 1969. 1 This drug has been effective in the management of patients with hyperprolactinemia with or without a demonstrable prolactin-secreting adenoma, growth hormone-secreting pituitary adenomas, postpartum lactation ...
Shlomo Melmed, Glenn D. Braunstein
openaire +3 more sources
Bromocriptine and Puerperal Seizures
Epidemiology, 1990Case reports have prompted concern that the use of bromocriptine mesylate to prevent lactation in the puerperium increases the risk of postpartum seizure. We conducted a record-based case-control study of postpartum seizures in three data bases to evaluate this relation.
Donna P. Funch +2 more
openaire +2 more sources
Quick-release bromocriptine for treatment of type 2 diabetes.
Current Drug Delivery, 2011Quick-release bromocriptine (bromocriptine-QR) (Cycloset) was approved in 2009 for treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine-QR has not been elucidated, but the drug may help resetting the circadian ...
N. Mikhail
semanticscholar +1 more source
BROMOCRIPTINE THERAPY IN ACROMEGALY
The Lancet, 1975Bromocriptine (CB-154, Sandoz) has been given to 21 acromegalic patients (11 female, 10 male) for a period of 6-10 months. The mean serum growth-hormone (G.H.) levels ranged from 10 mug/1 to 512 mug/1 before therapy. Bromocriptine suppressed G.H.
A. Gomez-Pan +6 more
openaire +3 more sources